Cargando…

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

Background: The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated. Methods: Two prospective single-arm phase II studies investigated either two cycles (study A: n = 19) or three cycles (study B: n = 33) of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2011
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082157/ https://www.ncbi.nlm.nih.gov/pubmed/21242586 http://dx.doi.org/10.1093/annonc/mdq564

Ejemplares similares

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
por: Bex, A, et al.
Publicado: (2020)

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Powles, T, et al.
Publicado: (2003)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Cytoreductive Nephrectomy: Still Necessary in 2021
por: Méjean, Arnaud, et al.
Publicado: (2022)

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
por: Fransen van de Putte, Elisabeth E., et al.
Publicado: (2023)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib
por: Furukawa, Junya, et al.
Publicado: (2016)

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Con
por: Kuusk, Teele, et al.
Publicado: (2022)

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
por: Wolter, P, et al.
Publicado: (2008)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2009)

Impact of Laparoscopic Partial Nephrectomy and Open Partial Nephrectomy on Outcomes of Clear Cell Renal Cell Carcinoma
por: Yu, Feng, et al.
Publicado: (2021)

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
por: Shamash, J, et al.
Publicado: (2011)

Comparative Studies of the Proteome, Glycoproteome, and N-Glycome of Clear Cell Renal Cell Carcinoma Plasma before and after Curative Nephrectomy
por: Gbormittah, Francisca O., et al.
Publicado: (2014)

Contrasting effects of sunitinib within in vivo models of metastasis
por: Welti, Jonathan C., et al.
Publicado: (2012)

Clearing the Killing Fields
por: O'Brien, Eoin
Publicado: (1995)

DNA topoisomerase I and II expression in drug resistantgerm cell tumours
por: Berney, D M, et al.
Publicado: (2002)

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
por: Shamash, J, et al.
Publicado: (2008)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma
por: Nagase, Kei, et al.
Publicado: (2021)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Cryoablation and immunotherapy: an overview of evidence on its synergy
por: Aarts, B. M., et al.
Publicado: (2019)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
por: Al-Lamki, Rafia S., et al.
Publicado: (2020)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Hormone replacement therapy as treatment of breast cancer--a phase II study of Org OD 14 (tibilone).
por: O'Brien, M., et al.
Publicado: (1996)

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2022)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor–Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer
por: Stewart, Grant D., et al.
Publicado: (2014)

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?
por: Berney, D M, et al.
Publicado: (2001)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dm4hhk962oc8v5upah3v5hkcf1